MicroRNA 199a-5p (miR-199a-5p)

MicroRNA 199a-5p (miR-199a-5p) is a highly conserved, small non-coding RNA that functions as a critical post-transcriptional regulator of gene expression by binding to the 3' untranslated regions (UTRs) of target messenger RNAs [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358286/]. It is derived from the miR-199a precursor and is predominantly expressed in the liver, heart, and lungs, where it modulates a wide range of biological processes including cell proliferation, apoptosis, autophagy, and metabolic homeostasis [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533444/]. In many cancers, such as hepatocellular carcinoma and non-small cell lung cancer, miR-199a-5p acts as a tumor suppressor by targeting oncogenic factors like HIF-1α, mTOR, and NF-κB1 [MDPI, https://www.mdpi.com/2072-6694/14/15/3741]. However, its dysregulation is also linked to pathological conditions such as cardiac hypertrophy, liver fibrosis, and atherosclerosis, where it may promote disease progression by suppressing protective genes like SIRT1 or Caveolin-1 [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533444/]. miR-199a-5p is currently being explored as a non-invasive diagnostic and prognostic biomarker due to its presence in circulating biofluids like plasma and serum [MDPI, https://www.mdpi.com/1422-0067/22/18/9819]. Therapeutically, it is a target for miRNA-based interventions, where miRNA mimics are used to restore its suppressive function in tumors, while antagomirs are investigated to block its pro-fibrotic or pro-hypertrophic effects [Codon Publications, https://www.ncbi.nlm.nih.gov/books/NBK549191/]. Additionally, miR-199a-5p levels influence the sensitivity of cancer cells to various chemotherapeutic agents, including cisplatin and doxorubicin, making it a potential target for overcoming drug resistance [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371045/]. The development of miR-199a-5p-targeted therapies faces challenges such as off-target effects and the need for efficient delivery systems to ensure stability and tissue-specific action [MDPI, https://www.mdpi.com/1422-0067/25/11/5844].

Other names

miR-199a-5phsa-miR-199a-5pmicroRNA-199a-5pmiR-199a

Drugs targeting miR-199a-5p primarily utilize miRNA mimics to restore its tumor-suppressive levels or antagomirs (antisense oligonucleotides) to inhibit its pathological overexpression in conditions like fibrosis and hypertrophy. These agents work by either supplementing the endogenous miRNA pool to enhance target mRNA degradation and translational repression or by sequestering the mature miRNA to prevent its interaction with target genes such as HIF-1α, SIRT1, and Caveolin-1.